{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:38:01Z","timestamp":1790393881526,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The epidermal growth factor receptor (EGFR) is a critical regulator of multiple oncogenic signaling cascades, including MAPK, PI3K\/AKT\/mTOR, and JAK\u2013STAT pathways, which collectively contribute to enhanced proliferation, angiogenesis, and resistance to apoptosis in cancer. Aberrant EGFR activation has been strongly associated with tumor progression and therapeutic resistance, underscoring its importance as a molecular target for anticancer interventions.\n                    <jats:italic>Ailanthus altissima<\/jats:italic>\n                    (\n                    <jats:italic>A. altissima<\/jats:italic>\n                    ), is known for its broad-spectrum anticancer potential although the underlying mechanism has not yet been clearly defined. Therefore, in present study, bioactive constituents of\n                    <jats:italic>A. altissima<\/jats:italic>\n                    were systematically analyzed for their ability to modulate proteins implicated in cancer pathogenesis and subsequently overlapped with hub genes differentially expressed across cancer grades. The common targets were mapped to lung cancer associated signaling pathways, revealing EGFR as a highly modulated node. Among the identified metabolites, neoschaftoside emerged as the top-ranked bioactive interacting with EGFR-related hub genes. Later, Molecular docking and molecular dynamics (MD) simulations demonstrated strong binding affinity and conformational stability of the EGFR neoschaftoside complex. Post-MD analyses, including principal component analysis (PCA) and dynamic cross-correlation matrix (DCCM) analysis, further indicated restricted global motions and enhanced correlated dynamics, confirming structural stabilization upon ligand binding. Collectively, these findings suggest that neoschaftoside may function as a promising lead compound capable of inhibiting EGFR activity through modulation of EGFR signaling, thereby suppressing oncogenic progression.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-33214-0","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T19:55:01Z","timestamp":1766692501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Decoding the molecular mechanism via systems biology-based insights into neoschaftoside from Ailanthus altissima targeting lung cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Sachin","family":"Gudasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini S.","family":"Kavalapure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriram D.","family":"Ranade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"33214_CR1","doi-asserted-by":"publisher","first-page":"102693","DOI":"10.1016\/j.canep.2024.102693","volume":"93","author":"J Zhou","year":"2024","unstructured":"Zhou, J. et al. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 93, 102693 (2024).","journal-title":"Cancer Epidemiol."},{"key":"33214_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","volume":"136","author":"C Li","year":"2023","unstructured":"Li, C. et al. Global burden and trends of lung cancer incidence and mortality. Chin. Med. J. 136, 1583\u20131590 (2023).","journal-title":"Chin. Med. J."},{"key":"33214_CR3","doi-asserted-by":"publisher","first-page":"104752","DOI":"10.1016\/j.compbiomed.2021.104752","volume":"136","author":"Z Khodabakhshi","year":"2021","unstructured":"Khodabakhshi, Z. et al. Non-small cell lung carcinoma histopathological subtype phenotyping using high-dimensional multinomial multiclass CT radiomics signature. Comput. Biol. Med. 136, 104752 (2021).","journal-title":"Comput. Biol. Med."},{"key":"33214_CR4","first-page":"545","volume":"4","author":"CB Simone","year":"2015","unstructured":"Simone, C. B., Burri, S. H. & Heinzerling, J. H. Novel radiotherapy approaches for lung cancer: Combining radiation therapy with targeted and immunotherapies. Transl. Lung Cancer Res. 4, 545\u2013552 (2015).","journal-title":"Lung Cancer Res."},{"key":"33214_CR5","doi-asserted-by":"crossref","unstructured":"Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L. & Paz-Ares, L. Lung cancer: Current therapies and new targeted treatments. Lancet 389, 299\u2013311 (2017).","DOI":"10.1016\/S0140-6736(16)30958-8"},{"key":"33214_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-025-02812-3","volume":"42","author":"NA Yusoh","year":"2025","unstructured":"Yusoh, N. A., Ahmad, H., Vallis, K. A. & Gill, M. R. Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies. Med. Oncol. 42, 1\u201322 (2025).","journal-title":"Med. Oncol."},{"key":"33214_CR7","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.3390\/ijms25168568","volume":"25","author":"E Stef\u00e0no","year":"2024","unstructured":"Stef\u00e0no, E. et al. An overview of altered pathways associated with sensitivity to platinum-based chemotherapy in neuroendocrine tumors: Strengths and prospects. Int. J. Mol. Sci. 25, 8568 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"33214_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu, K., Xie, F., Wang, F. & Fu, L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J. Hematol. Oncol. 15, 173 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"33214_CR9","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.3390\/cancers14143337","volume":"14","author":"A Koulouris","year":"2022","unstructured":"Koulouris, A., Tsagkaris, C., Corriero, A. C., Metro, G. & Mountzios, G. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: From mechanisms to new therapeutic strategies. Cancers 14, 3337 (2022).","journal-title":"Cancers"},{"key":"33214_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/diagnostics14010048","volume":"14","author":"L Fabbri","year":"2023","unstructured":"Fabbri, L. et al. From development to place in therapy of lorlatinib for the treatment of ALK and ROS1 rearranged non-small cell lung cancer (NSCLC). Diagnostics 14, 48 (2023).","journal-title":"Diagnostics"},{"key":"33214_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper, A. J., Sequist, L. V. & Lin, J. J. Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management. Nat. Rev. Clin. Oncol. 19, 499\u2013514 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"33214_CR12","first-page":"603","volume":"7","author":"YO Ohsaki","year":"2000","unstructured":"Ohsaki, Y. O. et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep. 7, 603\u2013610 (2000).","journal-title":"Oncol. Rep."},{"key":"33214_CR13","first-page":"187","volume":"7","author":"TC Liu","year":"2017","unstructured":"Liu, T. C., Jin, X., Wang, Y. & Wang, K. Role of epidermal growth factor receptor in lung cancer and targeted therapies. Am. J. Cancer Res. 7, 187\u2013197 (2017).","journal-title":"Am. J. Cancer Res."},{"key":"33214_CR14","doi-asserted-by":"crossref","unstructured":"Batra, U., Biswas, B., Prabhash, K. & Krishna, M. V. Differential clinicopathological features, treatments and outcomes in patients with exon 19 deletion and exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ Open. Respir Res. 10, e001492 (2023).","DOI":"10.1136\/bmjresp-2022-001492"},{"key":"33214_CR15","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.21037\/tcr-23-956","volume":"12","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q., Wang, R. & Xu, L. Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: A narrative review. Transl. Cancer Res. 12, 3764 (2023).","journal-title":"Transl. Cancer Res."},{"key":"33214_CR16","doi-asserted-by":"crossref","unstructured":"Dickerson, H. & Diab, A. Al Musaimi, O. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer: Current use and future prospects. Int. J. Mol. Sci. 25, 10008 (2024).","DOI":"10.3390\/ijms251810008"},{"key":"33214_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/cancers15030841","volume":"15","author":"G Gomatou","year":"2023","unstructured":"Gomatou, G., Syrigos, N. & Kotteas, E. Osimertinib resistance: Molecular mechanisms and emerging treatment options. Cancers 15, 841 (2023).","journal-title":"Cancers"},{"key":"33214_CR18","doi-asserted-by":"crossref","unstructured":"Gudasi, S. & Patil, M. B. Comprehensive review on anti-obesity effects of plant-derived compounds: evidence from 3T3-L1 adipocytes and high-fat diet models. Asp Mol. Med. 100089 (2025).","DOI":"10.1016\/j.amolm.2025.100089"},{"key":"33214_CR19","doi-asserted-by":"publisher","first-page":"114121","DOI":"10.1016\/j.jep.2021.114121","volume":"275","author":"X Li","year":"2021","unstructured":"Li, X. et al. Traditional uses, phytochemistry, and pharmacology of A. altissima (Mill.) swingle bark: a comprehensive review. J. Ethnopharmacol. 275, 114121 (2021).","journal-title":"J. Ethnopharmacol."},{"key":"33214_CR20","doi-asserted-by":"publisher","first-page":"11331","DOI":"10.3390\/app112311331","volume":"11","author":"D Caramelo","year":"2021","unstructured":"Caramelo, D. et al. Insights into the bioactivities and chemical analysis of A. altissima (Mill.) swingle. Appl. Sci. 11, 11331 (2021).","journal-title":"Appl. Sci."},{"key":"33214_CR21","first-page":"6022","volume":"15","author":"R Wang","year":"2018","unstructured":"Wang, R. et al. Antitumor activity of the A. altissima bark phytochemical ailanthone against breast cancer MCF-7 cells. Oncol. Lett. 15, 6022\u20136028 (2018).","journal-title":"Oncol. Lett."},{"key":"33214_CR22","first-page":"248","volume":"15","author":"R Desaipatti","year":"2025","unstructured":"Desaipatti, R., Kudatarkar, N. & Gudasi, S. In Silico screening and experimental validation of Carissa Carandas L. extract against cyclophosphamide-induced cardiotoxicity in Wistar rats. J. Appl. Pharm. Sci. 15, 248\u2013259 (2025).","journal-title":"J. Appl. Pharm. Sci."},{"key":"33214_CR23","doi-asserted-by":"crossref","unstructured":"Kavalapure, R. S. et al. Structure-guided development of Quinoline derivatives targeting Kinesin spindle protein. Bioorg. Med. Chem. Lett. 130278 (2025).","DOI":"10.1016\/j.bmcl.2025.130278"},{"key":"33214_CR24","doi-asserted-by":"crossref","unstructured":"Kambalyal, A. M. et al. Development of marker-based quantification methods for Diospyros Montana Roxb using DoE approach and in-silico anti-diabetic screening of selected phytoconstituents of the Diospyros genus. Nat. Prod. Res. 1\u20139 (2024).","DOI":"10.1080\/14786419.2024.2445205"},{"key":"33214_CR25","doi-asserted-by":"publisher","first-page":"108306","DOI":"10.1016\/j.bioorg.2025.108306","volume":"157","author":"SG Alegaon","year":"2025","unstructured":"Alegaon, S. G. et al. Design, synthesis and molecular dynamics simulations of thiazole-based hydrazones targeting MDA-MB-231 breast cancer cells. Bioorg. Chem. 157, 108306 (2025).","journal-title":"Bioorg. Chem."},{"key":"33214_CR26","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang, Z., Li, C., Kang, B., Gao, G. & Zhang, Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98\u2013W102 (2017).","journal-title":"Nucleic Acids Res."},{"key":"33214_CR27","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner, R. A. et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein\u2013ligand complexes. J. Med. Chem. 49, 6177\u20136196 (2006).","journal-title":"J. Med. Chem."},{"key":"33214_CR28","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate Docking and scoring. 1. Method and assessment of Docking accuracy. J. Med. Chem. 47, 1739\u20131749 (2004).","journal-title":"J. Med. Chem."},{"key":"33214_CR29","doi-asserted-by":"crossref","unstructured":"Bowers, K. J. et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In Proc. 2006 ACM\/IEEE Conf. Supercomputing, Vol. 84 (2006).","DOI":"10.1145\/1188455.1188544"},{"key":"33214_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10822-025-00645-w","volume":"39","author":"SG Alegaon","year":"2025","unstructured":"Alegaon, S. G., Ranade, S. D., Gharge, S., Kavalapure, R. S. & Ulaganathan, V. Computational and experimental repositioning of Quinoline analogues as KSP inhibitors: insights from free energy landscape and PCA analysis. J. Comput. Aided Mol. Des. 39, 1\u20137 (2025).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"33214_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LE Hendriks","year":"2024","unstructured":"Hendriks, L. E. et al. Non-small-cell lung cancer. Nat. Rev. Dis. Primers. 10, 71 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"33214_CR32","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.21037\/tlcr.2019.03.05","volume":"8","author":"A Shankar","year":"2019","unstructured":"Shankar, A. et al. Environmental and occupational determinants of lung cancer. Transl. Lung Cancer Res. 8, S31 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"33214_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2559.2011.03854.x","volume":"60","author":"KM Kerr","year":"2012","unstructured":"Kerr, K. M. Personalized medicine for lung cancer: New challenges for pathology. Histopathology 60, 531\u2013546 (2012).","journal-title":"Histopathology"},{"key":"33214_CR34","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.3390\/ijms221910827","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang, Y., Li, N., Wang, T. M. & Di, L. Natural products with activity against lung cancer: a review focusing on the tumor microenvironment. Int. J. Mol. Sci. 22, 10827 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"33214_CR35","first-page":"6022","volume":"15","author":"R Wang","year":"2018","unstructured":"Wang, R. et al. Antitumor activity of the Ailanthus altissima bark phytochemical ailanthone against breast cancer MCF-7 cells. Oncol. Lett. 15, 6022\u20136028 (2018).","journal-title":"Oncol. Lett."},{"key":"33214_CR36","doi-asserted-by":"publisher","first-page":"119436","DOI":"10.1016\/j.lfs.2021.119436","volume":"276","author":"KR Paudel","year":"2021","unstructured":"Paudel, K. R. et al. Rutin loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro. Life Sci. 276, 119436 (2021).","journal-title":"Life Sci."},{"key":"33214_CR37","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41598-018-19536-2","volume":"8","author":"F Sannino","year":"2018","unstructured":"Sannino, F. et al. Pseudoalteromonas haloplanktis TAC125 produces 4-hydroxybenzoic acid that induces pyroptosis in human A459 lung adenocarcinoma cells. Sci. Rep. 8, 1190 (2018).","journal-title":"Sci. Rep."},{"key":"33214_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.arbres.2017.07.012","volume":"54","author":"F Aguiar","year":"2018","unstructured":"Aguiar, F. et al. Overall survival analysis and characterization of an EGFR mutated non-small cell lung cancer (NSCLC) population. Arch. Bronconeumol. 54, 10\u201317 (2018).","journal-title":"Arch. Bronconeumol."},{"key":"33214_CR39","first-page":"3189","volume":"11","author":"X Qiu","year":"2021","unstructured":"Qiu, X. et al. Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Am. J. Cancer Res. 11, 3189 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"33214_CR40","doi-asserted-by":"crossref","first-page":"e26662","DOI":"10.1016\/j.heliyon.2024.e26662","volume":"10","author":"T Sun","year":"2024","unstructured":"Sun, T. et al. Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis. Heliyon 10, e26662 (2024).","journal-title":"Heliyon"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33214-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:04:00Z","timestamp":1769475840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33214-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33214"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33214-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies involving patients or animals as test objects. Informed consent was not required for this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"3328"}}